Alkermes Plc

Overview

Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development, and commercialization of drugs for the treatment of cancer, neurodegenerative and central nervous system (CNS) diseases. The company’s proprietary products include Aristada and Aristada Initio an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, a once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants license under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to pharmaceutical wholesalers, treatment providers, specialty distributors and pharmacies. Alkermes is headquartered in Dublin, Ireland.
Key Stats
Address
Connaught HSE, 1 Burlington Road, DUBLIN, Ireland
Headquarters

Ireland

Contact

353 1 7728000

No of Employees

2,245

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

ALKS [NASD]

Revenue (2020)

$1,039 m

-11.3% (2020 vs 2019)
Net Income (2020)

$-111 m

43.6% (2020 vs 2019)
Net Profit Margin

-11 %

36.5% (2020 vs 2019)
Market Cap *

$4,787 m

EPS *

$-0.7

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Alkermes PlcNovartis AGSanofiEli Lilly and Co
Key Information
Headquarters Ireland Switzerland France United States of America
Headquarter City DUBLIN BASEL PARIS INDIANAPOLIS
Headquarter State/Province - - - Indiana
No. of Employees 2,245 109,000 99,412 35,000
Entity Type Public Public Public Public

Products & Services

Alkermes applies its scientific expertise and technological know-how to develop novel medicines designed to help patients with CNS diseases. The company's key marketed, and pipeline products include the following.

Products
  • Products:
  • Marketed Products
  • Aristada – Schizophrenia
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Services
  • Contract Manufacturing:
  • Analytical Services
  • Clinical Dose
  • Etiam Rutrum Elit
  • Etiam Rutrum Elit
  • Etiam Rutrum Elit
  • Etiam Rutrum Elit
Brands
  • Aristada
  • Vivitrol
  • Aristada Initio
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Iain M. Brown Senior Vice President; Chief Financial Officer Senior Management 2021 53 Mr. Iain Brown has been the Chief Financial Officer and the Senior Vice President of the company since 2021. Prior...
Craig Hopkinson, M.D. Chief Medical Officer; Executive Vice President - Research & Development Senior Management 2020 54 Mr. Craig Hopkinson has been the Chief Medical Officer and Executive Vice President of Research and Development of the company...
Todd Nichols Chief Commercial Officer; Senior Vice President Senior Management 2019 - Mr. Todd Nichols has been the Chief Commercial Officer and the Senior Vice President of the company since 2019. Prior...
Richard F. Pops Chief Executive Officer; Chairman Executive Board 2011 55 Mr. Richard F. Pops has been the Chairman and the Chief Executive Officer of the company since 2011. Prior to...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In April, the company and Sarissa Capital Management signed an agreement, in which Sarissa Capital…
2021 Regulatory Approval In March, the US FDA granted Orphan Drug Designation for company's nemvaleukin alfa for the…
2021 Regulatory Approval In June, the company received the US FDA approval for its LYBALVI (olanzapine and samidorphan)…
2021 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Alkermes US Holdings Inc

Address

852 Winter Street, Waltham
United States of America

Telephone

1 781 6096000

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
07 Apr 2021 Alkermes Enters into Agreement with Merck Partnership Alkermes Plc; Merck & Co Inc
02 Nov 2020 Alkermes Plc Enters Phase I Clinical Trial Agreement with Pharmaceutical Product Development LLC for diroximel fumarate DR (GDCT0402193) Contract Service Agreement Alkermes Plc; Alkermes Plc Pharmaceutical Product Development LLC; Pharmaceutical Product Development LLC
02 Nov 2020 Alkermes Plc Enters Phase I Clinical Trial Agreement with Pharmaceutical Product Development LLC for diroximel fumarate DR (GDCT0402186) Contract Service Agreement Alkermes Plc; Alkermes Plc Pharmaceutical Product Development LLC; Pharmaceutical Product Development LLC
02 Nov 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
02 Nov 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
19 Oct 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

128

Active Jobs

39

Posted

30

Closed

Job Trends

Latest Jobs

Job title Company Country
Associate Director, Artwork and Package Design Alkermes Plc United States
Vice President, Biostatistics Alkermes Plc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar